{"id":4503,"date":"2012-01-18T00:00:00","date_gmt":"2012-01-18T00:00:00","guid":{"rendered":"https:\/\/mci.pl\/excellent-results-of-mci-techventures-and-mci-bioventures\/"},"modified":"2012-01-18T00:00:00","modified_gmt":"2012-01-18T00:00:00","slug":"excellent-results-of-mci-techventures-and-mci-bioventures","status":"publish","type":"post","link":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures","title":{"rendered":"Excellent results of MCI.TechVentures and MCI.BioVentures"},"content":{"rendered":"<p>Two of the funds belonging to the MCI Group, MCI.TechVen<!--more-->tures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%.<\/p>\n<p>\u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which the companies are operating and to their development stages and they assume active cooperation with the management teams. The appropriateness of such approach is confirmed by the achieved results. In case of the MCI.TechVentures fund, the investment strategy assumes focusing on companies being in the growth stage, active in the market segments having the high growth rate and those segments, the leaders of which achieve the scale synergy and create potential for consolidation of the market,\u00e2\u0080\u009d said Sylwester Janik, manager of MCI.TechVentures, management board member and partner of MCI Management SA.<\/p>\n<p>\u00e2\u0080\u009cThe companies from the medical and biotechnological sector in which MCI.BioVentures has invested fared well during last year and in total they achieved 25% increase of revenues in comparison to year 2010. In May 2011, Genomed SA &#8211; a company included in the fund\u00e2\u0080\u0099s portfolio &#8211; had its debut at NewConnect, and in December 2011 we performed the first full exit from an investment by selling MedCasco to a strategic investor and achieving an attractive rate of return from the investment. By realizing these actions we commenced a phase of de-investment, which is beneficial to investor since it enables realization of profits. The above actions results in an increase in value of investment certificates of MCI.BioVentrures FIZ by 28.20%, which constitutes one of the best results of investment funds in year 2011. The prospects for the sector for this year seem to be equally interesting, so we intend to continue creating excellent results,\u00e2\u0080\u009d says Grzegorz Gromada, manager of MCI.BioVentures and venture partner of MCI Management SA.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two of the funds belonging to the MCI Group, MCI.TechVen<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"protect_children":false,"inline_featured_image":false,"footnotes":""},"categories":[56,57],"tags":[],"class_list":["post-4503","post","type-post","status-publish","format-standard","hentry","category-news","category-press-releases"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"k.karkoszka\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Grupa MCI - Wiod\u0105cy inwestor technologiczny na rynkach Wschodz\u0105cej Europy\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI\" \/>\n\t\t<meta property=\"og:description\" content=\"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2012-01-18T00:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2012-01-18T00:00:00+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#blogposting\",\"name\":\"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI\",\"headline\":\"Excellent results of MCI.TechVentures and MCI.BioVentures\",\"author\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/author\\\/k-karkoszka#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/#organization\"},\"datePublished\":\"2012-01-18T00:00:00+01:00\",\"dateModified\":\"2012-01-18T00:00:00+01:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#webpage\"},\"articleSection\":\"News, Press Releases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mci.pl\\\/en\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/kategoria\\\/news#listItem\",\"name\":\"News\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/kategoria\\\/news#listItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/mci.pl\\\/kategoria\\\/news\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#listItem\",\"name\":\"Excellent results of MCI.TechVentures and MCI.BioVentures\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#listItem\",\"position\":3,\"name\":\"Excellent results of MCI.TechVentures and MCI.BioVentures\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/mci.pl\\\/kategoria\\\/news#listItem\",\"name\":\"News\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/#organization\",\"name\":\"Grupa MCI Capital S.A.\",\"description\":\"Wiod\\u0105cy inwestor technologiczny na rynkach Wschodz\\u0105cej Europy\",\"url\":\"https:\\\/\\\/mci.pl\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/author\\\/k-karkoszka#author\",\"url\":\"https:\\\/\\\/mci.pl\\\/en\\\/author\\\/k-karkoszka\",\"name\":\"k.karkoszka\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/431f3f10126e2c9d5362b29445b7f41031d128fff924dea17851efeab3ebfe86?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"k.karkoszka\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#webpage\",\"url\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures\",\"name\":\"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI\",\"description\":\"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \\u00e2\\u0080\\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/excellent-results-of-mci-techventures-and-mci-bioventures#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/author\\\/k-karkoszka#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/author\\\/k-karkoszka#author\"},\"datePublished\":\"2012-01-18T00:00:00+01:00\",\"dateModified\":\"2012-01-18T00:00:00+01:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/mci.pl\\\/en\\\/\",\"name\":\"Grupa MCI\",\"description\":\"Wiod\\u0105cy inwestor technologiczny na rynkach Wschodz\\u0105cej Europy\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/mci.pl\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI","description":"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which","canonical_url":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#blogposting","name":"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI","headline":"Excellent results of MCI.TechVentures and MCI.BioVentures","author":{"@id":"https:\/\/mci.pl\/en\/author\/k-karkoszka#author"},"publisher":{"@id":"https:\/\/mci.pl\/en\/#organization"},"datePublished":"2012-01-18T00:00:00+01:00","dateModified":"2012-01-18T00:00:00+01:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#webpage"},"isPartOf":{"@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#webpage"},"articleSection":"News, Press Releases"},{"@type":"BreadcrumbList","@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/mci.pl\/en#listItem","position":1,"name":"Home","item":"https:\/\/mci.pl\/en","nextItem":{"@type":"ListItem","@id":"https:\/\/mci.pl\/kategoria\/news#listItem","name":"News"}},{"@type":"ListItem","@id":"https:\/\/mci.pl\/kategoria\/news#listItem","position":2,"name":"News","item":"https:\/\/mci.pl\/kategoria\/news","nextItem":{"@type":"ListItem","@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#listItem","name":"Excellent results of MCI.TechVentures and MCI.BioVentures"},"previousItem":{"@type":"ListItem","@id":"https:\/\/mci.pl\/en#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#listItem","position":3,"name":"Excellent results of MCI.TechVentures and MCI.BioVentures","previousItem":{"@type":"ListItem","@id":"https:\/\/mci.pl\/kategoria\/news#listItem","name":"News"}}]},{"@type":"Organization","@id":"https:\/\/mci.pl\/en\/#organization","name":"Grupa MCI Capital S.A.","description":"Wiod\u0105cy inwestor technologiczny na rynkach Wschodz\u0105cej Europy","url":"https:\/\/mci.pl\/en\/"},{"@type":"Person","@id":"https:\/\/mci.pl\/en\/author\/k-karkoszka#author","url":"https:\/\/mci.pl\/en\/author\/k-karkoszka","name":"k.karkoszka","image":{"@type":"ImageObject","@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/431f3f10126e2c9d5362b29445b7f41031d128fff924dea17851efeab3ebfe86?s=96&d=mm&r=g","width":96,"height":96,"caption":"k.karkoszka"}},{"@type":"WebPage","@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#webpage","url":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures","name":"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI","description":"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/mci.pl\/en\/#website"},"breadcrumb":{"@id":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures#breadcrumblist"},"author":{"@id":"https:\/\/mci.pl\/en\/author\/k-karkoszka#author"},"creator":{"@id":"https:\/\/mci.pl\/en\/author\/k-karkoszka#author"},"datePublished":"2012-01-18T00:00:00+01:00","dateModified":"2012-01-18T00:00:00+01:00"},{"@type":"WebSite","@id":"https:\/\/mci.pl\/en\/#website","url":"https:\/\/mci.pl\/en\/","name":"Grupa MCI","description":"Wiod\u0105cy inwestor technologiczny na rynkach Wschodz\u0105cej Europy","inLanguage":"en-US","publisher":{"@id":"https:\/\/mci.pl\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Grupa MCI - Wiod\u0105cy inwestor technologiczny na rynkach Wschodz\u0105cej Europy","og:type":"article","og:title":"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI","og:description":"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which","og:url":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures","article:published_time":"2012-01-18T00:00:00+00:00","article:modified_time":"2012-01-18T00:00:00+00:00","twitter:card":"summary_large_image","twitter:title":"Excellent results of MCI.TechVentures and MCI.BioVentures - Grupa MCI","twitter:description":"Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%. \u00e2\u0080\u009cThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which"},"aioseo_meta_data":{"post_id":"4503","title":null,"description":null,"keywords":null,"keyphrases":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"created":"2022-08-04 17:42:09","updated":"2026-09-10 06:04:18","focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/mci.pl\/en\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/mci.pl\/kategoria\/news\" title=\"News\">News<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tExcellent results of MCI.TechVentures and MCI.BioVentures\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/mci.pl\/en"},{"label":"News","link":"https:\/\/mci.pl\/kategoria\/news"},{"label":"Excellent results of MCI.TechVentures and MCI.BioVentures","link":"https:\/\/mci.pl\/en\/excellent-results-of-mci-techventures-and-mci-bioventures"}],"_links":{"self":[{"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/posts\/4503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/comments?post=4503"}],"version-history":[{"count":0,"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/posts\/4503\/revisions"}],"wp:attachment":[{"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/media?parent=4503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/categories?post=4503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mci.pl\/en\/wp-json\/wp\/v2\/tags?post=4503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}